Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Tarsus Pharmaceuticals, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 92 | 105 | +13 |
| Shares | 21.4M | 29.8M | +8.36M (+39.0%) |
| Value | $387.3M | $529.4M | +$142.1M (+36.7%) |
New holders (25)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
Sold out (12)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Assenagon Asset Management S.A. | 146,194 | $2.64M |
| Algert Global LLC | 47,152 | $852.0K |
| Invesco Ltd. | 41,769 | $754.8K |
| Jacobs Levy Equity Management, Inc | 41,667 | $752.9K |
| Susquehanna International Group, LLP | 32,435 | $586.1K |
| D. E. Shaw & Co., Inc. | 23,451 | $423.8K |
| Innovis Asset Management LLC | 13,141 | $237.5K |
| Sargent Investment Group, LLC | 10,045 | $181.5K |
| Public Employees Retirement System of Ohio | 9,331 | $169.0K |
| Simplex Trading, LLC | 5,383 | $97.0K |
| Dorsey Wright & Associates | 1,289 | $23.3K |
| Signaturefd, LLC | 572 | $10.3K |